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September 2016 because there were very few patients in this age group in clinical trials. 8, 11 Although there have been several observational studies reporting oldest-old populations receiving intravenous tPA after stroke, the sample sizes have been limited and the focus has been on those aged ≥80 years rather than those aged ≥90 years, and thus it is unclear whether extremely advanced age is an independent risk factor for hemorrhagic conversion after intravenous thrombolysis. 7, [12] [13] [14] Given these limited data on patients aged ≥90 years, the purpose of this study is to (1) determine the frequency of intravenous tPA treatment and nontreatment in ≥90-year olds compared with younger patients, (2) identify characteristics associated with treatment versus nontreatment in the ≥90-year olds, and (3) determine how post-tPA outcomes varied according to the age group.
Methods
Get With The Guidelines (GWTG)-Stroke is an ongoing, voluntary, continuous registry, and performance improvement initiative. 15 The participating sites collect and enter deidentified patient-level data on clinical and demographic characteristics, diagnostic testing, treatments, adherence to quality measures, and in-hospital outcomes in patients hospitalized with stroke. GWTG-Stroke, launched in April 2003 as a national stroke quality improvement program, is available to any hospital in the United States. Hospitals have continued to join over the past decade. GWTG-Stroke includes a patient-management platform that provides real-time decision support, logic checks, and smart form controls to enhance data accuracy, and real-time online reporting features. Trained hospital personnel ascertain consecutive patients admitted with stroke by prospective clinical identification, retrospective identification using International Classification of Diseases-Ninth Revision discharge codes, or a combination. Prospective identification includes regular surveillance of emergency department records (ie, presenting symptoms and chief complaints), ward census logs, or neurological consultations. The eligibility of each patient with stroke is confirmed at chart review before abstraction. After data extraction by trained personnel at each hospital, deidentified patient data are entered into the GWTG-Stroke database using a web-based patient-management tool (Outcome, A Quintiles Company, Cambridge, MA). Data elements collected include patient demographics, medical history and comorbidities, initial brain imaging findings, in-hospital treatment and events, discharge treatment, counseling, mortality, and discharge destination. 16 
Patient Population
We analyzed data from fully participating GWTG-Stroke registry sites from January 2009 to April 2013. A patient flow diagram, showing inclusion and exclusion criteria, is given in Figure 1 . To determine the proportion of patients eligible for and receiving treatment in different age strata, we included all directly arriving patients with ischemic stroke with complete documentation of tPA treatment, excluding transfers and in-hospital strokes. For analyses of predictors of tPA treatment and outcomes after treatment, we analyzed patients arriving to the hospital within 120 minutes of symptom onset, excluding patients who were not eligible for treatment because of the time of presentation or the presence of contraindications and warnings; patients transferred to another acute care facility or who left against medical advice; patients with missing National Institutes of Health Stroke Scale (NIHSS) or discharge destination; and sites with high missing rates for systolic blood pressure, body mass index, fasting blood glucose, and international normalized ratio (ie, sites with > 25% of admitted patients missing all 4 laboratory and physiological values). Finally, we provide descriptive statistics on the small number of ≥100-year olds treated with tPA.
Outcomes and Safety
In-hospital outcomes among patients eligible for and treated with tPA were compared among 4 age groups: 18 to 64, 65 to 79, 80 to 89, and ≥90 years. Age categories were defined before the analysis and were based on commonly used categories from earlier literature. The primary outcomes of interest were as follows: discharge disposition (home, rehabilitation, skilled nursing facility, long-term care, intermediate care facility, hospice, or death), independent ambulation at discharge, in-hospital mortality, symptomatic intracerebral hemorrhage (sICH), and systemic bleeding complications related to thrombolysis within 36 hours. Hospice discharge was defined as transfer to an inpatient facility specializing in comprehensive palliative care for terminally ill patients with life expectancy <6 months, in accordance with the US Medicare definition.
Statistical Analysis
Age was categorized as 18 to 64, 65 to 79, 80 to 89, and ≥90 years. Proportions of patients arriving in time for treatment, with contraindications to tPA, and who were treated with tPA were tabulated and graphed. Baseline characteristics, comorbidities, laboratory data, and medications before admission were described for patients at least 90 years of age, overall and then by those who received tPA and those who did not using proportions for categorical variables and medians with 25th and 75th percentiles for continuous variables. The differences in these characteristics were compared using χ 2 tests for categorical row variables and Wilcoxon rank-sum tests for continuous row variables. Differences in means and proportions with 95% confidence intervals are presented.
Factors associated with tPA use in older patients were assessed using logistic regression with generalized estimating equations to account for within-hospital correlations. Outcomes among patients receiving tPA were also compared between old patients (≥90) and the 3 younger age groups. Age groups were treated as nominal in the models. Models adjusted for both patient and hospital characteristics. Patient characteristics were sex, race/ethnicity, arrival mode from emergency medical services, arrival time during off hours, onset to arrival time, calendar year of admission, medical history variables (atrial fibrillation, prosthetic heart valve, earlier stroke/transient ischemic attack, coronary artery disease/previous myocardial infarction, carotid stenosis, diabetes mellitus, peripheral vascular disease, hypertension, smoking, and dyslipidemia), independent ambulation before admission, on anticoagulants or antiplatelets before admission, fasting blood glucose, systolic blood pressure, body mass index, and international normalized ratio. Hospital characteristics were percent NIHSS score recorded by the site, teaching/academic hospital status, rural location, geographic region, hospital size (number of beds), annual volume of ischemic stroke admissions, annual volume of tPA administration, and the Joint Commission Primary Stroke Center status. The linearity of the relationship between each continuous variable and the log odds of tPA use was assessed; as a result, NIHSS score and percent NIHSS recorded by the site were included in the model as linear splines with knot points at 13% and 94%, respectively.
Missing rates for patient variables included in the model were <15%; most variables were missing <5% of the time. Therefore, single imputation was used to reduce missingness in the models. For continuous variables, missing values were imputed to the age group-specific median. Missing values for categorical variables were imputed to the most common category. Hospital characteristics were not imputed.
All significance tests were 2 sided, and P<0.05 were considered statistically significant. All analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).
Results
Between January 2009 and April 2013, a total of 802 388 patients with ischemic stroke meeting study criteria were directly admitted to 1380 GWTG-Stroke hospitals in the United States. Among these patients, 67 713 were of age ≥90 years; 207 918 were of age 80 to 89 years; 268 397 were of age 65 to 79 years, and 258 360 were of age 18 to 64 years. Figure 2 and Table I in the online-only Data Supplement show the age-specific rates of arrival within 2 hours of onset, the presence of contraindications to tPA, and rates of use of tPA. The rate of tPA use declined with age: from 7.1% at age 18 to 64 years to 5.6% at age ≥90 years. Patients aged ≥90 years arrived within 2 hours of documented last known well time more often than younger age groups: 21.5% for age ≥90 years, 20.6% for age 80 to 89 years, 19.7% for age 65 to 79 years, and 18.9% for age 18 to 64 years (P <0.0001). Considering only patients arriving within 2 hours of onset who had no documented contraindication to lytic treatment, tPA treatment occurred in 67.4% patients over age 90 years, 80.6% of patients 80 to 89 years, 84.6% of patients 65 to 79 years, and 86.6% of patients age 18 to 64 years (P<0.0001). Table 1 shows the univariate characteristics of under 2-hour arriving, tPA-eligible patients ≥90 years who did and did not receive tPA. The median age of tPA recipients was 92 (25th to 75th percentiles, 91-94; range, 90-107), and centenarians accounted for just 1.6% (42/2585). As shown in Table II in the online-only Data Supplement, independent patient-level predictors of receiving tPA among nonagenarian and centenarian patients were as follows: white, non-Hispanic race/ethnicity, arrival by emergency medical services, arrival during on hours, earlier arrival, later calendar year, more severe neurological deficit, being independent in ambulation before stroke, and having a lower international normalized ratio. Independent 
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The characteristics of patients who received tPA, according to different age strata, are shown in Table III in the onlineonly Data Supplement. Women accounted for a strikingly higher proportion of tPA patients at older ages, including 40% of patients aged 18 to 64 years, 47% of patients aged 65 to 79 years, 62% of patients aged 80 to 89 years, and 74% of patients aged ≥90 years (P<0.0001). Patients aged ≥90 years were also markedly more often white, arrived by ambulance, had severe presenting stroke deficits, and had a medical history of atrial fibrillation and coronary artery disease. These patients were less often current smokers or independently ambulatory before the index stroke. Differences in clinical outcomes among the age groups are shown in Tables 2 and 3 and Figure 3 . The rate of discharge to home was only 13.5% in the population aged ≥90 years, but the rate of discharge to home or acute rehabilitation was 31.4%. Hospice care at discharge was a frequent outcome in patients aged ≥90 years. In-hospital mortality occurred in 16.2%, but discharge to hospice care occurred in an additional 20.2%. Age ≥90 years was an independent predictor, compared with each of the 3 younger age groups, of less frequent discharge to home, discharge to home or acute rehabilitation, and independent ambulatory status at discharge, and more frequent in-hospital mortality or discharge to hospice care. Age ≥90 years was also independently associated with more sICH compared with the youngest age group, 18 to 64 years, but was not statistically different compared with patients aged 65 to 79 or 80 to 89 years.
In exploratory analysis comparing patients of age 90 to 99 years with those of ≥100 years, centenarians had later onset to arrival times, less frequent hypertension, equal discharge to home but less frequent discharge to acute rehabilitation, and nonsignificant increase in symptomatic intracranial hemorrhage but significant increase in systemic hemorrhage (Table  IV in the online-only Data Supplement).
Discussion
In this study of a national quality registry, the rate of tPA use among patients aged ≥90 years eligible for lytic therapy was modestly lower than in younger age groups, but still substantial, with more than two thirds of eligible patients receiving lytic therapy. The likelihood of being discharged to home and having independent ambulation at discharge was reduced in tPA-treated patients aged ≥90 years compared with tPA-treated younger patients, and the risk of in-hospital mortality or discharge to hospice care was increased. In contrast, age ≥90 years was not associated with an increased risk of tPA-related sICH compared with younger tPA-treated patients age 18 to 89 years, and the rate of sICH was modest in the oldest old population.
The frequency of tPA treatment for eligible nonagenarians and centenarians increased during the study period from 2009 to 2013. These findings likely reflect the increasing general use of tPA in the United States 16 and increasing comfort of clinical teams in treating very old patients with acute ischemic stroke specifically. 
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Our findings with regard to mortality confirm and extend those of the few previous investigations that have examined individuals aged ≥90 years. We found a further increase in mortality and discharge to hospice care among nonagenarians and centenarians compared with octogenarians. These results accord with previous smaller studies also delineating increased mortality among patients aged ≥90 years compared with octogenarians.
17, 18 In our study, the higher mortality rate was not a result of any increased vulnerability to sICH. Higher unadjusted rates of mortality were driven, in part, by more severe neurological deficits at presentation and more frequent medical comorbidities at presentation. Even after adjustment for these factors, age ≥90 years was independently associated with elevated mortality. In part, this association arose from an increased use of comfort care and hospice care in the nonagenarian and centenarian population. Whereas moderately to severely disabled outcomes are often acceptable to younger patients with stroke, very old patients and their families may desire either an excellent outcome or death. 19 In this study, post-thrombolytic sICH in nonagenarians and centenarians (6.1%) was not more frequent than the rate of 6.4% observed in the 2 pivotal National Institute of Neurological Disorders and Stroke tPA clinical trials. 11 There was an increase in the rate of sICH from aged 18 to 64 years through age 65 to 79 years and again through age 80 to 89 years, but then a tendency toward a decline among those aged ≥90 years. These findings accord with 2 previous smaller series evaluating thrombolysis in patients over age 90 years, which found no difference in sICH rates between octogenarians and nonagenarians/centenarians. 17, 18 This study confirms the prognostic importance of age for clinical efficacy outcomes among patients treated with tPA. For example, the rate of discharge to home or acute rehabilitation was only 31.4% among nonagenarians and centenarians, and the odds of discharge to home or acute rehabilitation were 6-fold lower in the patients aged ≥90 years than among aged 18 to 64 years. This observational study could not directly address whether the outcomes with lytic therapy among tPAtreated age ≥90 patients were better than they would have been without lytic therapy. Few patients age ≥90 years have been enrolled or separately reported in randomized trials of tPA therapy. For example, analysis of the public data set of the 2 pivotal National Institute of Neurological Disorders and Stroke-tPA trials shows no patients aged ≥90 years were enrolled. 11 In the IST 3 (Third International Stroke Trial), which placed a special emphasis on enrolling older patients, most elderly patients were aged 80 to 89 years. Only 7% of patients were aged ≥90 years, and results in this subgroup were not separately reported. 13 IST 3 did confirm that patients aged ≥80 years benefitted from tPA therapy even though their outcomes were not as good as younger lytic-treated patients. However, further analyses of patients aged ≥90 years in IST 3 and in the forthcoming TESPI trial (Thrombolysis in Elderly Stroke Patients in Italy) are desirable.
This study has several limitations. The data reported are dependent on the accuracy and completeness of abstraction from the medical record. To optimize data quality, the GWTG-Stroke Program includes detailed training of site chart abstractors, standardized case definitions and coding instructions, predefined logic and range checks on data fields at data entry, audit trails, and regular data quality reports for all sites. 20 The data are from voluntary participating hospitals that include many certified stroke centers and teaching hospitals with quality improvement initiatives; hence, these data may not be representative of nonparticipating hospitals. We are unable to determine the effect of tPA compared with controls because of the study's observational design. We focused on early arriving patients who could be treated within 2 hours because treatment beyond 3 hours is not included in the Food and Drug Administration label; therefore, our findings may not generalize to later-arriving patients. It is possible that residual and unmeasured confounders contribute to observed age group differences. We did not have information on prestroke or poststroke cognitive impairment or dementia, which would be increasing common at more advanced ages. Finally, the outcomes reported in this study are short term. No data on postdischarge stroke-related outcomes were collected in the GWTG-Stroke Program during the study period, so the longer-term outcomes among nonagenarians and centenarians could not be directly investigated. The results of our large national cohort indicate that a preponderance of tPA-eligible nonagenarians and centenarians are treated with intravenous thrombolysis, albeit not as high a proportion as younger age groups. Among patients age ≥90 years treated with intravenous tPA symptomatic hemorrhage rates are comparable to younger patients, whereas rates of good functional outcome are lower and mortality is higher than in younger patients. This knowledge may be useful to clinicians in counseling patients and their families about their expectations after treatment with tPA and can aid in the decision-making process for acute stroke therapy in very old patients.
Sources of Funding
The Get With The Guidelines-Stroke (GWTG-Stroke) program is provided by the American Heart Association/American Stroke Association. GWTG-Stroke is sponsored, in part, by Medtronic and has been funded in the past through support from Boeringher- employee of the University of California, which holds a patent on retriever devices for stroke. Dr Saver is an employee of the University of California. The University of California, Regents receive funding for Dr Saver's services as a scientific consultant regarding trial design and conduct to Medtronic/Covidien, Stryker, Neuravia, BrainsGate, Pfizer, Squibb, Boehringer Ingelheim (prevention only), ZZ Biotech, and St. Jude Medical. Dr Saver has served as an unpaid site investigator in multicenter trials run by Lundbeck for which the UC Regents received payments on the basis of clinical trial contracts for the number of subjects enrolled. Dr Saver serves as an unpaid consultant to Genentech advising on the design and conduct of the PRISMS trial; neither the University of California nor Dr Saver received any payments for this voluntary service. The University of California has patent rights in retrieval devices for stroke.Dr Smith reports serving as a member of the GWTG Steering Committee. Age-specific rates of arrival within 2 hours of onset, presence of contraindications to tPA, and rates of use of tPA with absolute percent differences and 95% confidence limits. All differences p<0.001 by chi-square test. This information is graphically displayed in Figure 1 . 
